These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15674414)

  • 41. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.
    Murphy KM; Levis M; Hafez MJ; Geiger T; Cooper LC; Smith BD; Small D; Berg KD
    J Mol Diagn; 2003 May; 5(2):96-102. PubMed ID: 12707374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
    Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS
    Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
    Schnittger S; Schoch C; Kern W; Hiddemann W; Haferlach T
    Acta Haematol; 2004; 112(1-2):68-78. PubMed ID: 15179006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of FLT3 in haematopoietic malignancies.
    Stirewalt DL; Radich JP
    Nat Rev Cancer; 2003 Sep; 3(9):650-65. PubMed ID: 12951584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia.
    Torelli GF; Guarini A; Porzia A; Chiaretti S; Tatarelli C; Diverio D; Maggio R; Vitale A; Ritz J; Foa R
    Br J Haematol; 2005 Jul; 130(1):43-50. PubMed ID: 15982343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia.
    Kratz CP; Böll S; Kontny U; Schrappe M; Niemeyer CM; Stanulla M
    Leukemia; 2006 Feb; 20(2):381-3. PubMed ID: 16341038
    [No Abstract]   [Full Text] [Related]  

  • 48. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
    Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel FLT3 point mutation in acute myeloid leukaemia.
    Piccaluga PP; Bianchini M; Martinelli G
    Lancet Oncol; 2003 Oct; 4(10):604. PubMed ID: 14554237
    [No Abstract]   [Full Text] [Related]  

  • 50. FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL).
    Kabir NN; Rönnstrand L; Kazi JU
    Med Oncol; 2013 Mar; 30(1):462. PubMed ID: 23335073
    [No Abstract]   [Full Text] [Related]  

  • 51. Genomic structure of human FLT3: implications for mutational analysis.
    Abu-Duhier FM; Goodeve AC; Wilson GA; Care RS; Peake IR; Reilly JT
    Br J Haematol; 2001 Jun; 113(4):1076-7. PubMed ID: 11442505
    [No Abstract]   [Full Text] [Related]  

  • 52. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group.
    Xu F; Taki T; Eguchi M; Kamada N; Ishii E; Endo M; Hayashi Y
    Leukemia; 2000 May; 14(5):945-7. PubMed ID: 10803532
    [No Abstract]   [Full Text] [Related]  

  • 53. Functional genomics: improving cancer prognosis and drug development.
    Mariani SM
    MedGenMed; 2003 Mar; 5(1):18. PubMed ID: 12827079
    [No Abstract]   [Full Text] [Related]  

  • 54. TET2 mutations in childhood leukemia.
    Langemeijer SM; Jansen JH; Hooijer J; van Hoogen P; Stevens-Linders E; Massop M; Waanders E; van Reijmersdal SV; Stevens-Kroef MJ; Zwaan CM; van den Heuvel-Eibrink MM; Sonneveld E; Hoogerbrugge PM; van Kessel AG; Kuiper RP
    Leukemia; 2011 Jan; 25(1):189-92. PubMed ID: 21042320
    [No Abstract]   [Full Text] [Related]  

  • 55. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene.
    Hou P; Liu D; Xing M
    Leukemia; 2007 Oct; 21(10):2216-8. PubMed ID: 17525723
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunophenotyping as a guide for targeted therapy.
    Sonneveld P; Pieters R
    Best Pract Res Clin Haematol; 2003 Dec; 16(4):629-44. PubMed ID: 14592647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia.
    Nicholson L; Knight T; Matheson E; Minto L; Case M; Sanichar M; Bomken S; Vormoor J; Hall A; Irving J
    Genes Chromosomes Cancer; 2012 Mar; 51(3):250-6. PubMed ID: 22072526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenomics suggests new treatment approach for leukaemia.
    Senior K
    Drug Discov Today; 2002 Aug; 7(15):791-2. PubMed ID: 12546960
    [No Abstract]   [Full Text] [Related]  

  • 59. Cuplike nuclear morphology in pediatric B-cell acute lymphoblastic leukemia.
    Richardson AI; Li W
    Blood; 2018 Jul; 132(4):457. PubMed ID: 30049734
    [No Abstract]   [Full Text] [Related]  

  • 60. Genomic analysis drives tailored therapy in poor risk childhood leukemia.
    Harrison CJ
    Cancer Cell; 2012 Aug; 22(2):139-40. PubMed ID: 22897843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.